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APOBEC3Cer APOBEC3 cytidine deaminases inhibit a variety of retroviruses, including Vif-
deﬁcient HIV-1. These host proteins are packaged into viral particles and inhibit the replication of virus in
new target cells. A3G and A3F are known to be efﬁciently packaged into HIV-1 virions by binding to 7SL RNA
through the Gag NC domain; however, the packaging mechanisms of other APOBEC3 proteins are poorly
deﬁned. We have now demonstrated that APOBEC3C (A3C) can be efﬁciently packaged into HIV-1 virions
that are deﬁcient for viral genomic RNA. Inhibition of the encapsidation of 7SL RNA into HIV-1 virions
blocked the packaging of A3G, but not A3C. While the NC domain is required for efﬁcient packaging of A3G,
deletion of this domain had little effect on A3C packaging into HIV-1 Gag particles. A3C interacted with HIV-1
Gag which was MA domain-dependent and RNA-dependent. Deletion of the MA domain of HIV-1 Gag
inhibited A3C but not A3G packaging into HIV-1 Gag particles. Thus, A3G and A3C have evolved to use
distinct mechanisms for targeting retroviruses.
© 2008 Published by Elsevier Inc.Introduction
Human cytidine deaminase apolipoprotein B mRNA-editing cata-
lytic polypeptide-like 3G (APOBEC3G, A3G) and other APOBEC3
proteins (Jarmuz et al., 2002) are related to a family of proteins that
also includes apolipoprotein B-editing catalytic subunit 1 (APOBEC1),
APOBEC2, and activation-induced cytidine deaminase (AID). These
proteins have cytidine deaminase activities that modify RNA or DNA.
A3G was the ﬁrst AID/APOBEC proteins to be identiﬁed as a potent
inhibitor of HIV-1 in the absence of Vif (Sheehy et al., 2002).
Subsequently, various APOBEC3 proteins were shown to have broad
antiviral activity against a wide range of retroviruses (Bieniasz, 2004;
Chiu and Greene, 2006; Cullen, 2006; Goff, 2004; Harris and
Liddament, 2004; Malim, 2006; Navarro and Landau, 2004; Rose
et al., 2004; Turelli and Trono, 2005; Yu, 2006), endogenous
retroviruses (Esnault et al., 2005), LINE-1 and Alu retrotransposons
(Bogerd et al., 2006; Chen et al., 2006; Chiu et al., 2006; Hulme et al.,
2007; Muckenfuss et al., 2006; Niewiadomska et al., 2007; Stenglein
and Harris, 2006; Turelli et al., 2004b), hepatitis B virus (Bonvin et al.,ogy and Immunology, Johns
Wolfe Street, Baltimore, MD
lsevier Inc.2006; Rosler et al., 2005; Turelli et al., 2004a,b; Xu et al., 2007; Zhang
et al., 2008), adeno-associated virus (Chen et al., 2006), and DNA virus
promoter activities (Zhang et al., 2008).
APOBEC3 proteins can be packaged into diverse retroviruses that
mediate potent antiviral functions in newly infected target cells.
Virion-packaged A3G molecules induce cytidine deamination of viral
DNA during reverse transcription in newly infected target cells (Harris
et al., 2003; Lecossier et al., 2003; Mangeat et al., 2003; Mariani et al.,
2003; Suspene et al., 2004; Xu et al., 2007; Yu et al., 2004b; Zhang
et al., 2003). A3G and another APOBEC3 protein, A3F, also reduce the
accumulation of viral reverse transcription products (Bishop et al.,
2006; Guo et al., 2006; Iwatani et al., 2007; Kaiser and Emerman,
2006; Li et al., 2007; Luo et al., 2007; Mbisa et al., 2007; Yang et al.,
2007) and inhibit proviral DNA formation (Luo et al., 2007; Mbisa
et al., 2007).
To suppress the restriction imposed by APOBEC3 factors, HIV-1
encodes a regulatory protein, Vif, which triggers the degradation of
APOBEC3 proteins through polyubiquitination and proteasomal
degradation (Conticello et al., 2003; Liu et al., 2005, 2004; Marin
et al., 2003; Mehle et al., 2004; Sheehy et al., 2003; Stopak et al., 2003;
Yu et al., 2003). Vif recruits Cul5 and ElonginB/C E3 ubiquitin ligase
(Kobayashi et al., 2005; Liu et al., 2005; Luo et al., 2005; Mehle et al.,
2004; Yu et al., 2003, 2004c) through an HCCHmotif (Luo et al., 2005)
and virus-speciﬁc BC-box (Mehle et al., 2004; Yu et al., 2004c),
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the A3G or A3F through distinct interfaces (Marin et al., 2003; Russell
and Pathak, 2007; Schrofelbauer et al., 2006; Simon et al., 2005; Tian
et al., 2006), and three functional domains in the carboxy-terminal
region of this Vif protein interact with Cul5 and ElonginB/C. The HCCH
motif (Luo et al., 2005), which binds zinc (Mehle et al., 2006; Xiao
et al., 2007a, 2006) and contains a consensus sequence Hx2YFx-
CFx4Φx2AΦx7–8Cx5H (Xiao et al., 2007b), is required for Cul5
binding. The SLQXLA motif, a virus-speciﬁc BC-box (Mehle et al.,
2004; Yu et al., 2004c) that mediates the interactionwith ElonginsB/C,
is conserved between HIV-1 and other lentiviral Vif molecules. An-
other Cul5-binding motif, LPx4L, is located downstream of this BC-
box. In addition tomediating APOBEC3 degradation, Vif is also thought
to reduce the translation of A3G and to suppress APOBEC3 through a
ubiquitin/proteasome-independent mechanism (Opi et al., 2007;
Stopak et al., 2003).
Encapsidation of APOBEC3G (A3G) into HIV-1 particles is mediated
by retroviral Gag molecules (Alce and Popik, 2004; Cen et al., 2004;
Douaisi et al., 2004; Luo et al., 2004; Navarro et al., 2005; Schafer et al.,
2004; Zennou et al., 2004). In particular, the nucleocapsid domain
(NC) of HIV-1 Gag is known to be required for efﬁcient A3G packaging.
The interaction that occurs between HIV-1 Gag and A3G in virus-
producing cells is believed to be the driving force behind A3G
packaging; this also requires cellular RNA(s) (Douaisi et al., 2004; Luo
et al., 2004; Navarro et al., 2005; Schafer et al., 2004; Svarovskaia et al.,
2004; Zennou et al., 2004). Since HIV-1 Gag particles lack viral
genomic RNA, it appears that viral genomic RNA is not required for
A3G packaging. However, this issue is still controversial (Khan et al.,
2005; Svarovskaia et al., 2004).Fig. 1.HIV-1 RNA is not required for A3C packaging. (A) Diagrams of the HIV-1 constructs ΔPo
ΔPolΔEnv and GAGINS. (C) Immunoblot analysis of the packaging of A3C into wild-type an
expression vector plus pCul5ΔNEDD8 into 293T cells as indicated. 48 h after transfection, cell
against CAp24 to detect viral Gag proteins and an MAb against the HA tag to detect A3C-HAOur recent data indicate that 7SL RNA is selectively packaged into
HIV-1 through an interaction with the NC domain of HIV-1 Gag (Tian
et al., 2007) and the virion packaging of A3G or A3F involves a
selective interaction between 7SL RNA and A3G or A3F (Wang et al.,
2007; Wang et al., 2008). However, the packaging mechanisms of
other APOBEC3 proteins have not been well characterized to date.
APOBEC3C (A3C), the single domain APOBEC3 protein, has been
detected in HIV-1 virions (Langlois et al., 2005; Yu et al., 2004a). It has
weak anti-HIV-1 activity (Dang et al., 2006; Langlois et al., 2005; Yu et
al., 2004a), induces less cytidine deamination in HIV-1 DNA than A3G
(Yu et al., 2004a), and has reduced ability to inhibit HIV-1 reverse
transcription and integration compared to A3G (Luo et al., 2007).
In the present study, we have explored the viral determinants of
A3C packaging. Our data indicate that the packaging of A3C differs
from that of A3G in that the NC domain of HIV-1 Gag is apparently not
important for A3C packaging. Reducing 7SL RNA encapsidation into
HIV-1 virions also did not affect A3C packaging. However, we found
that the MA domain of HIV-1 Gag is important for the interaction
between Gag and A3C and for the efﬁcient packaging of A3C; in the
case of A3G, it is not essential for either of these processes. Thus, these
two, and perhaps other APOBEC3 cytidine deaminases have evolved to
use distinct mechanisms to gain access into retroviral particles.
Results
Viral genomic RNA is not required for A3C virion packaging
The viral determinant of A3C virion packaging has not yet been
identiﬁed. To address the role of viral genomic RNA in thelΔEnv and pGAGINS. (B) Immunoblot analysis of the virion incorporation of A3C-HA into
d NC mutant HIV-1 virions. pNL4-3 and pNL2/2 were co-transfected with the A3C-HA
lysates and virion pellets were prepared and analyzed by immunoblotting with an MAb
.
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in ΔPolΔEnv particles and in particles containing only Gag molecules
(GagINS). The pΔPolΔEnv construct contains all the 5′RNA sequences
upsteam of the gag coding sequence, including TAR, PolyA, PBS, DIS,
SD, and the packaging signal (Fig. 1A); it does not express Pol, Env, Vif,
Vpr, Vpu, or Nef. The Gag amino acid sequence of pGagINS is identical
to that of pΔPolΔEnv and could be expressed in the absence of Rev
(Qiu et al., 1999). However, pGagINS lacks all the 5′ viral RNA
sequences, including the viral RNA packaging sequences upstream of
the Gag coding region (Fig. 1A). Both constructs produce VLPs
consisting only of Gag protein of viral origin.
We found that the expression of A3C-HA in all types of transfected
cells was comparable (Fig. 1B, lanes 1–3). Gag VLPs were produced
from both pΔPolΔEnv- and pGagINS-transfected 293T cells (Fig. 1B,
lanes 5 and 6). VLP-associated A3C-HA was comparable in Gag VLPFig. 2. Virion incorporation of A3C is NC-independent. (A) Immunoblot analysis of the pack
packaging of A3G-HA into HIV-1 Gag NCS or P2LZ particles. (C) Co-sedimentation of A3C-H
constructs were co-transfected with an A3C-HA expression vector into 293T cells. At 48 h a
ultracentrifugation through a 20% sucrose cushion. Gag particle pellets were resuspended in 0
an SW41 rotor (Beckman) at 22,000 rpm for 16 h at 4 °C. The fractions were collected and ana
against CAp24 to detect NCS and P2LZ Gagmolecules. (D) Expression vectors for A3C-HA and
cell and viral lysates were prepared and analyzed by immunoblotting using anMAb against th
Gag molecules. (E) Quantiﬁcation of A3C-HA or A3G-HA packaging into Gag NCS or P2LZ pafrom pΔPolΔEnv-transfected cells (Fig. 1B, lane 5) and from pGagINS-
transfected cells (Fig.1B, lane 6). As expected, no A3C-HAwas detected
in the supernatant of control vector-transfected cells, which did not
generate VLPs (Fig. 1B, lane 4). Similar results for A3G has been
previously reported (Luo et al., 2004).
To further address whether viral genomic RNA plays a role in virion
incorporation of A3C, we compared the levels of virion-associated A3C
in wild-type pNL4-3 virus and the viral genomic RNA packaging
mutant pNC2/2. pNC2/2 contains ﬁve amino acid substitutions in the
N-terminal zinc ﬁnger of the HIV-1 NC region and packages only
approximately 15% of the viral genomic RNA. Again, the expression of
A3C-HA was comparable in both types of transfected cells (Fig. 1C,
lanes 1–3). A3C degradation was inhibited by co-expression of
Cul5ΔNEDD8 in this experiment (Fig. 1C). A3C was detected in the
pNL4-3 virions (Fig. 1C, lane 5) and to a similar degree in the pNC2/2aging of A3C-HA into HIV-1 Gag NCS or P2LZ particles. (B) Immunoblot analysis of the
A with HIV-1 Gag NCS or P2LZ particles in sucrose density gradients. GagNCS or P2LZ
fter transfection, culture supernatants were separated from cell debris by ﬁltration and
.5 ml PBS and layered onto a ﬁve-step sucrose density gradient (20–60%), centrifuged in
lyzed by immunoblotting with anMAb against the HA tag to detect A3C-HA and anMAb
A3G-HAwere co-transfected with NCS or P2LZ into 293T cells. At 48 h after transfection,
e HA tag to detect A3C-HA or A3G-HA and anMAb against CAp24 to detect NCS and P2LZ
rticles. Packaging of A3C-HA or A3G-HA into Gag NCS particles was set to 100%.
Fig. 3. Overexpression of SRP19 proteins impairs the packaging of A3G, but not A3C.
(A) Overexpression of SRP19 proteins inhibits A3G encapsidation into HIV-1 virions.
HIV-1ΔVif virions plus A3G-HA were produced from transfected 293T cells in the
absence (lane 2) or presence of exogenous SRP19-myc proteins (lane 3). Packaging of
A3G-HA into HIV-1ΔVif virions was analyzed by immunoblotting with an anti-HA Mab
to detect A3G-HA and an anti-CAp24 Mab to detect viral Gag proteins. SRP19-myc
proteins were detected with an anti-myc Mab. Secretion of A3G-HA in the absence of
HIV-1ΔVif was used as a negative control (lane 1). (B) Overexpression of SRP19 proteins
does not inhibit A3C encapsidation into HIV-1 virions. HIV-1ΔVif virions plus A3C-HA
were produced from transfected 293T cells in the absence (lane 2) or the presence of
exogenous SRP19-myc proteins (lane 3). Packaging of A3C-HA into HIV-1ΔVif virions
was analyzed by immunoblotting with the antibodies described in (A). Secretion of
A3C-HA in the absence of HIV-1ΔVif was used as a negative control (lane 1).
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in the supernatant of control vector-transfected cells, which did not
generate HIV-1 virions (Fig. 1C, lane 4). Similar results for A3G has
been previously reported (Luo et al., 2004). Thus, these results
indicated that A3C packaging is independent of viral genomic RNA.
Moreover, like A3G, VLP containing only Gag molecules could still
package human A3C.
The NC domain of Gag is important for the packaging of A3G, but not
A3C, into HIV-1 particles
Previous studies have demonstrated that A3G binds to the
nucleocapsid (NC) domain of the Gag polyprotein during virion
assembly and that the packaging of A3G into HIV-1 particles requires
the Gag NC domain (Alce and Popik, 2004; Cen et al., 2004; Douaisi
et al., 2004; Luo et al., 2004; Navarro et al., 2005; Schafer et al., 2004;
Zennou et al., 2004). To examine the role of the NC domain in A3C
packaging, we compared the encapsidation of A3C (Fig. 2A) and A3G
(Fig. 2B) into HIV-1 Gag VLPs containing NC (GagNCS) and into Gag
derivatives that lacked NC (GagP2LZ) but could still produce VLPs (Luo
et al., 2004). 293T cells were co-transfected with a plasmid encoding
A3C-HA or A3G-HA plus either pGagNCS or pGagP2LZ. The cell lysates
of transfected cells were then analyzed by immunoblotting with an
anti-HA antibody to detect A3C-HA (Fig. 2A) or A3G-HA (Fig. 2B), and
the viral products were analyzed by immunoblotting with an anti-
CAp24 antibody. This analysis indicated that similar levels of A3C-HA
were packaged into pGagNCS and pGagP2LZ particles (Fig. 2A).
In contrast, packaging of A3G-HA into pGagP2LZ particles was
signiﬁcantly reduced when compared to that into pGagNCS particles
(Fig. 2B).
To further determine whether A3C could be packaged into NC-
deﬁcient HIV-1Gag VLPs, 293T cells were co-transfected with A3C-HA
and either pGagNCS or pGagP2LZ. VLPs in the supernatant were
collected and resolved on sucrose density gradients, as described
previously (Dettenhofer and Yu, 1999). Gradient fractions were
analyzed by immunoblotting with anti-HA or anti-CAp24 antibody.
As shown in Fig. 2C, the peak distribution of A3C-HA coincided with
that of GagNCS. VLPs formed by GagP2LZ molecules (Fig. 2C, bottom
panel) were slightly lighter than GagNCS particles (Fig. 2C, top panel).
However, A3C-HA still co-fractionated with the GagP2LZ molecules
(Fig. 2C, bottom panel). These data indicate that A3C molecules were
indeed packaged into NC-deleted Gag particles and shared the same
density as the corresponding Gag particles.
To further investigate this apparent requirement of NC for A3G but
not A3C packaging, we co-transfected 293T cells with A3C-HA and
A3G-HA expression vectors with pGagNCS or pGagP2LZ. The cell
lysates of transfected cells and Gag VLP were analyzed by Immuno-
blotting (Fig. 2D), with anti-HA (top panel) and anti-CAp24 (bottom
panel). Clearly, packaging of A3G-HA was signiﬁcantly reduced in the
pGagP2LZ particles (Fig. 2D, lane 6) when compared to the GagNCS
particles (lane 5). In contrast, little difference was detected between
GagNCS and GagP2LZ particles in terms of A3C-HA packaging (Fig. 2D).
In repeated experiments, A3G packaging into GagP2LZ particles was
reduced by approximately 85% when compared to GagNCS particles
(Fig. 2E), but A3C packaging into GagP2LZ particles was not
signiﬁcantly reduced (Fig. 2E). Apparently, the viral determinants for
the packaging of A3C and A3G are different.
Inhibition of 7SL RNA packaging reduces A3G, but not A3C, packaging
into virions
7SL (SRP) RNA is the RNA component of the signal recognition
particle (SRP) RNP complex, which also contains one copy each of the
SRP72, SRP68, SRP54, SRP19, SRP14, and SRP9 proteins. 7SL RNA, but
not the SRP proteins, is packaged into HIV-1 virions (Onafuwa-Nuga
et al., 2006), suggesting that HIV-1 packages free 7SL RNA but not 7SLRNA that is part of an SRP RNP complex. Overexpression of the 7SL
RNA binding protein SRP19 inhibits 7SL RNA packaging into HIV-1
virions (Wang et al., 2007). Consistent with our previous observations,
overexpression of SRP19 in the present study inhibited A3G packaging
into HIV-1 virions (Fig. 3A). However, its overexpression had little
effect on the packaging of A3C (Fig. 3B). SRP19 overexpression also did
not affect the intracellular expression of A3C (Fig. 3B, lanes 1 to 3).
Examination of the virions revealed that the packaging of A3C into
HIV-1 virions in the absence of SRP19 (Fig. 3B, lane 2) was not
signiﬁcantly different from that into HIV-1 virions produced in the
presence of SRP19 (Fig. 3B, lane 3). Thus, inhibiting 7SL RNA packaging
into HIV-1 virions did not affect A3C packaging. Deletion of the NC
domain of HIV-1 Gag also did not affect A3C packaging. Since both
A3G and 7SL RNA packaging require the NC domain of HIV-1 Gag,
these data indicate that A3C packaging does not rely on 7SL RNA.
The MA domain of HIV-1 Gag is required for efﬁcient A3C packaging
Since GagP2LZ lacks NC, P1, and P6 domains of HIV-1 Gag and still
packages A3C, we then asked whether thematrix (MA) domainwithin
HIV-1 Gag plays a role in its packaging. For this purpose, we analyzed
the packaging of A3C in the presence of full-length HIV-1 Gag (GAG-
myc) and an MA deletion construct Src ΔMA GAG-myc. SrcΔMA GAG-
myc contains an in-frame deletion of the MA domain, and the mem-
brane targeting function of MA is replaced by the v-src myristylation
signal (Dong et al., 2005). SrcΔMA GAG-myc produced Gag VPL
particles (Fig. 4B, upper panel) with densities of ~1.15–1.16 g/ml
(Fig. 4B, lower panel). Both the full-length Gag and MA-deﬁcient Gag
produced Gag particles efﬁciently (Fig. 4C), and the expression of A3C-
HA was comparable in both cell types (Fig. 4C, top lanes 1–3). As
expected, no A3C protein was detected in the supernatant of control
vector-transfected cells, which did not generate Gag particles (Fig. 4C,
lane 1). A3C-HA packaging into SrcΔMAGAG-myc particles was clearly
reduced when compared to that into GAG-myc particles (Fig. 4C,
compare lanes 2 and 3). In contrast, no difference in A3G packaging
was detected between the GAG-myc and SrcΔMAGAG-myc particles
(Fig. 4D, compare lanes 2 and 3). No A3G protein was detected in the
supernatant of control vector-transfected cells, which did not generate
Gag particles (Fig. 4D, lane 1).
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deﬁcient Gag particles, we co-transfected A3C-HA and A3G-HA with
GAG-myc or SrcΔMAGAG-myc into 293T cells, then analyzed the cellFig. 4. Inﬂuence of HIV-1 MA on A3C and A3G packaging. (A) Diagrams of HIV-1 full-length
The culture supernatants of SrcΔMAGAG-myc transfected 293T cells were harvested by ﬁltr
100,000 ×g on a 20–60% linear sucrose gradient for 15 h. Analysis was via Immunoblot anal
panel). (C) Immunoblot analysis of the packaging of A3C-HA into HIV-1 Gag-myc or SrcΔMA
SrcΔMAGAG-myc. Quantitative analysis, calculated as the relative ratio of A3C-HA and A3G-H
below. The VLP encapsidation of APOBEC-HA protein was analyzed after normalizing the m
were set to 1. (D) Comparison of the packaging of A3C-HA and A3G-HA into MA-deleted Gag
transfected with Gag-myc or SrcΔMAGAG-myc into 293T cells. At 48 h after transfection, cell
HA tag to detect A3C-HA or A3G-HA and an MAb against myc to detect HIV-1 full-length Glysates of the transfected cells and Gag particles by immunoblotting.
Although the intracellular expression of A3C-HA in SrcΔMAGAG-myc-
expressing cells (Fig. 4E, lane 3) was similar to that in GAG-mycGag and MA deletion SrcΔMAGAG-myc constructs. (B) The SrcΔMAGAG-myc forms VLP.
ation and ultracentrifugation through 20% sucrose cushion, and then centrifugation at
ysis by using mAb against CAp24 (upper panel). Density analysis is show below (lower
GAG-myc. (D) Immunoblot analysis of the packaging of A3G-HA into HIV-1 Gag-myc or
A in SrcΔMAGAGVLP as compared to A3C-HA and A3G-HA in HIV-1 GAG VLP, is shown
yc antigen content. Values for the HIV-1 GAG VLP incorporation of APOBEC-HA protein
particles from co-expressing cells. Expression vectors for A3C-HA and A3G-HAwere co-
and viral lysates were prepared and analyzed by immunoblotting using MAb against the
ag-myc and truncated SrcΔMAGAG-myc molecules.
Fig. 5. (A) A3C-HA binds full-length HIV-1 Gag but not MA-deleted Gag molecules. A3C-HA or control plasmids were cotransfected with HIV-1 Gag-myc or SrcΔMAGAG-myc. At 48 h
after transfection, cell lysates were prepared and immunoprecipitated with an anti-HA antibody conjugated to beads. Co-precipitated samples were analyzed by immunoblotting
using an MAb against the HA tag to detect A3C-HA and an MAb against myc to detect HIV-1 full-length Gag-myc and truncated SrcΔMAGAG-mycmolecules. (B) A3C-HA binds HIV-1
MA protein but weaker than binds full-length HIV-1 Gag. A3C-HA was cotransfected with HIV-1 Gag-myc or HIV-1 MA-myc. 48 h after transfection, cell lysates were prepared and
immunoprecipitated with an anti-myc antibody. Co-precipitated samples were analyzed by immunoblotting using an MAb against the HA tag to detect A3C-HA and an MAb against
myc to detect HIV-1 full-length Gag-myc and MA-myc molecules. (C) Sedimentation of human A3C and A3G in sucrose gradients. 293T cells which transfected A3C-HA expression
vector. 48 h after transfection, cell lysates were prepared were lysed, and cell debris was removed by centrifugation at 10,000 ×g for 15 min. Supernatants were treated with RNAse A
or RNase inhibitor for 30 min at 37 °C and centrifuged at 260,800 ×g for 4 h. Different fractions were analyzed by immunoblotting with a MAb against the HA tag for the detection of
APOBEC-HA. (D) A3C-HA binds HIV-1 Gag-myc and is disrupted by RNase treatment. Co-immunoprecipitationwas performed as described above. One aliquot of the sample was ﬁrst
treated with RNase (1.5 μg/ml) at 37 °C for 30 min before co-immunoprecipitation.
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was detected in SrcΔMAGAG-myc particles (Fig. 4E, lane 6) than in
GAG-myc particles (Fig. 4E, lane 5). At the same time, the packaging of
A3G-HA into these two types of particles was not signiﬁcantly affected
(Fig. 4E, compare lane 5 and 6). Since A3C-HA and A3G-HA were co-
expressed with either GAG-myc or SrcΔMAGAG-myc, it is clear that
the packaging of A3C and A3G was differentially affected by the MA-
domain deletion.
The interaction of A3C with HIV-1 Gag is MA domain-dependent and
RNA-dependent
Our data indicate that A3G binds HIV-1 Gag but not to NC domain-
deleted Gag molecules, and this inefﬁcient interaction with NC-
deleted Gag is also correlated with poor packaging of A3G into these
Gagmutant particles (Luo et al., 2004). To determinewhether A3C also
interacts with HIV-1 Gag, we used co-immunoprecipitation experi-
ments to characterize the intracellular interaction between Gag and
A3C. HIV-1 GAG-myc or SrcΔMAGAG-myc was co-transfected with
A3C-HA into 293T cells. At 48 h after transfection, A3C-HA was
immunoprecipitated from the cell lysates using an anti-HA antibody.
The results indicated that the full-length HIV-1 GAG-myc was co-
precipitated with A3C-HA (Fig. 5A, lane 8). As a control, GAG-myc was
not detected in the absence of A3C-HA (Fig. 5A, lane 7), indicating a
speciﬁc interaction between HIV-1 Gag and A3C. In contrast to the
full-length Gag, SrcΔMAGAG-myc did not interact efﬁciently with
A3C-HA (Fig. 5A, lane 6), despite the fact that SrcΔMAGAG-myc was
expressed at a level comparable to that of Gag-myc (Fig. 5A, compare
lanes 2 and 4). Thus, A3C packaging into HIV-1 Gag particles appears
to be mediated through an interaction between A3C and HIV-1 Gag,
and the MA domain of Gag is required for efﬁcient interaction.However, MA domain alone interacted less efﬁciently with A3C than
the full length Gag molecule (Fig. 5B).
Cellular RNA may play a role in A3C packaging into HIV-1 Gag
particles since we observed that A3C was associated with high-
molecular-weight complexes in 293T cell lysates when analyzed
through a sucrose velocity gradient (Fig. 5C, top panel, fractions 10 to
13). After treatment with RNase A, A3C-HA was largely detected in
fraction 1 to 3 of the sucrose velocity gradient (Fig. 5C, bottom panel),
suggesting that A3C is largely associated with cellular complexes that
contain RNA. The interaction between HIV-1 Gag and A3C was also
sensitive to RNase A treatment (Fig. 5D). Interaction between A3C and
HIV-1 Gag (Fig. 5D, lane 5) was largely disruptedwhen the samplewas
ﬁrst treated with RNase A (Fig. 5D, lane 6). The MA domain of HIV-1
Gag has been reported to have RNA binding activity (Burniston et al.,
1999; Lochrie et al., 1997; Ott et al., 2005; Purohit et al., 2001). Thus,
the interaction between HIV-1 Gag and A3C is MA-dependent and
requires the presence of RNA.
Discussion
The packaging of APOBEC3 proteins into HIV-1 virions is believed
to be essential to their anti-viral activity in newly infected target cells;
however, the viral determinants of APOBEC3 packaging have not been
well characterized. Although it has previously been reported that A3G
packaging is dependent upon an interaction with the nucleocapsid
(NC) domain of HIV-1 Gag and that this interaction requires an RNA
bridge (Douaisi et al., 2004; Khan et al., 2005; Luo et al., 2004; Navarro
et al., 2005; Schafer et al., 2004; Svarovskaia et al., 2004; Wang et al.,
2007; Zennou et al., 2004). The data reported here indicate that the
viral determinants for the packaging of A3C are distinct from those for
A3G. HIV-1 genomic RNA appeared to be dispensable for the
77T. Wang et al. / Virology 377 (2008) 71–79packaging of A3C (Fig. 1) as well as A3G (Alce and Popik, 2004; Burnett
and Spearman, 2007; Cen et al., 2004; Douaisi et al., 2004; Khan et al.,
2005; Luo et al., 2004; Navarro et al., 2005; Schafer et al., 2004; Wang
et al., 2008; Zennou et al., 2004), however, although the Gag molecule
could mediate both A3C and A3G packaging, we found that the MA
domain was required for the efﬁcient packaging of A3C but not A3G
into Gag particles (Fig. 4). On the other hand, A3G packaging requires
the NC domain of Gag, which was dispensable for A3C packaging
(Figs. 2).
We and others have previously shown that the virion encapsida-
tion of A3G depends on the NC domain of HIV-1 Gag (Alce and
Popik, 2004; Burnett and Spearman, 2007; Cen et al., 2004; Douaisi
et al., 2004; Luo et al., 2004; Navarro et al., 2005; Schafer et al.,
2004; Zennou et al., 2004). Recently, we have observed that A3G
speciﬁcally interacts with 7SL RNA (Wang et al., 2007), which is
likely a key mediator of its packaging; this 7SL RNA is bound by A3G
in both virus-producing cells and mature virions (Tian et al., 2007;
Wang et al., 2007). 7SL RNA is more selectively packaged into HIV-1
virions than other abundant cellular RNAs (Tian et al., 2007). In
particular, the NCp7 domain of HIV-1 Gag, and speciﬁcally the N-
terminal basic region and the basic linker region, were found to be
important for efﬁcient 7SL RNA packaging (Tian et al., 2007). We and
others have further showed that these regions of NC are important
for the virion packaging of cytidine deaminase A3G (Burnett and
Spearman, 2007; Luo et al., 2004). Inhibiting 7SL RNA encapsidation
also inhibited A3G and A3F packaging into HIV-1 virions (Wang
et al., 2007, 2008). Thus it is likely that 7SL RNA serves as a bridging
factor between Gag and A3G and mediate A3G packaging into the
virions.
In contrast to the results obtained for A3G, deletion of the NC
domain had little effect on A3C packaging in the present study (Fig. 2).
The particles produced by NC-deleted Gag molecules had a lighter
density than the Gag particles containing NC (Fig. 2). In both cases,
A3C co-peaked with the respective Gag particles (Fig. 2). This lack of
requirement for NC in A3C packaging was more clearly demonstrated
by co-expression of A3C and A3G in the same virus-producing cells. In
this case, a clear requirement for NC was seen in the case of A3G but
not A3C (Fig. 2D). Thus, it is likely that the NC domain and 7SL RNA do
not mediate A3C packaging. This conclusion is further supported by
the observation that limiting 7SL encapsidation inhibited the packa-
ging of A3G but not A3C (Fig. 3).
In the present study, we have also made the observation that
deletion of the MA domain of HIV-1 Gag inhibited the packaging of
A3C but not A3G. There are several possible reasons why the MA
domain might be critical for A3C packaging. One is that the MA
domain targets Gag molecules to certain intracellular sites during
virus assembly that have a high concentration of A3C molecules,
resulting in a passive packaging of A3C into virus; in the same way,
MA-deleted Gag molecules could be targeted to different sites that
have a low concentration of A3C, resulting in reduced A3C packaging.
Alternatively, HIV-1 Gag may interact with A3C either directly or
indirectly to recruit A3C into virions. Consistent with this interpreta-
tion, we have observed an interaction between HIV-1 Gag and A3C in
virus-producing cells. In this scenario, the MA domain would be
important for mediating the Gag-A3C interaction, a prediction
supported by our ﬁnding that MA-deleted Gag showed a reduced
level of interaction with A3C. Along the observations that MA domain
of Gag is important for its interaction with A3C, we have also found
that the interaction is RNA-dependent. Treatment of RNase A
disrupted the interaction between Gag and A3C. (Fig. 5D, lane 6)
Although NC domain is the most prominent RNA binding domain in
Gag and is largely responsible for selective packaging of genomic RNA
(Berkowitz et al., 1996), MA domain was shown to be able to bind
genomic viral and non-viral mRNA and tRNAs in the absence of NC
(Bukrinskaya et al., 1992; Ott et al., 2005). It is likely that MA domain
plays a redundant role in Gag RNA binding activity (Ott et al., 2005). Itis reasonable to speculate that cellular RNA(s) may serve as a bridging
factor between Gag and A3C and mediate A3C packaging. We have
shown in previous studies that 7SL RNA mediates A3G and A3F
packaging through NC domain of Gag (Wang et al., 2007, 2008), and it
would be interesting to further identify which cellular RNA is involved
in A3C packaging.
It is possible that in addition to the MA domain of HIV-1 Gag, other
viral determinant(s) also mediate A3C virion packaging. We have
observed that the packaging of A3C into HIV-1 Gag particles was less
efﬁcient than that of A3G (Figs. 2D and 4E). However, other people
have reported that both A3C and A3G are packaged efﬁciently into
HIV-1 virions (Yu et al., 2004a). Further study will be required to
determine whether other viral determinant(s) in addition to Gag also
mediate A3C virion packaging.
Taken together, our results indicate that human APOBEC3 proteins
have apparently evolved to use distinct mechanisms to target
retroviruses. Understanding the precise mechanisms involved in
virion packaging of APOBEC3 proteins may lead to novel develop-
ments that can enhance the packaging of APOBEC3 proteins and the
anti-viral activities of these molecules.
Materials and methods
Plasmid construction
pNL4-3 was obtained from the AIDS Research Reagents Program,
Division of AIDS, NIAID, NIH (Cat.# 114). The HIV-1 construct
ΔPolΔEnv (Lee and Yu, 1998) and Gag expression vectors pGAGINS
(Qiu et al., 1999), pGagNCS, and pGagP2LZ (Luo et al., 2004), Gag-myc
and SrcΔMAGag-myc (Dong et al., 2005) have been previously
described. A3G-HA and SRP19-myc expression vectors have been
previously described (Wang et al., 2007). The HIV-1 MAwas ampliﬁed
by RT-PCR using HIV-1 Gag MA forward primer: 5′ GTACGCTAGC
GCCATGGGAGCCCGCGCC AGC-3′; reverse primer: 5′-GTAC AAGCTTT-
CAAAGATCTTCTTCTGATATGAGTTTTTGTTCGTAGTTCTGGCT CACCTG-3′
containing NheI and Hind III sites, respectively, and a C-terminal c-
myc tag. The PCR product was cloned into pcDNA3.1 to generate HIV-1
MA-myc. A3C-HAwas generously provided by Dr. Michael Malim, and
pNC2/2 was generously provided by Dr. Robert Gorelick.
Antibodies and cell lines
The following antibodies were used for this study: Anti-CAp24
monoclonal antibody (mAb), obtained from the AIDS Research Reagents
Program, Division of AIDS, NIAID, NIH; anti-myc mAb (Sigma, Cat.
#M5546), and anti-HA mAb (Covance, Cat. # MMS-101R-10000). 293T
cells were maintained in Dulbecco's modiﬁed Eagle's medium (DMEM,
Invitrogen) with 10% fetal bovine serum and penicillin/streptomycin
(D-10 medium) and passaged upon conﬂuence.
Transfection and virus puriﬁcation
DNA transfections were carried out using Lipofectamine 2000
(Invitrogen) as described by the manufacturer. At 48 h after
transfection, virion-associated viral proteins were prepared from cell
culture supernatants and separated from cellular debris by centrifuga-
tion at 3000 rpm for 30 min in a Sorvall RT 6000B centrifuge and
ﬁltration through a 0.22-μmpore-size membrane. Virus particles were
concentrated by centrifugation through a 20% sucrose cushion at
100,000 ×g for 1.5 h in a Sorvall Ultra80 ultracentrifuge.
Immunoblot analysis
Cells were collected 48 h after transfection. Cell and viral lysates
were prepared as previously described (Tian et al., 2007). Cells
(1×105) were lysed in 1× loading buffer (0.08 M Tris, pH 6.8, with 2.0%
78 T. Wang et al. / Virology 377 (2008) 71–79SDS, 10% glycerol, 0.1 M dithiothreitol, and 0.2% bromophenol blue).
The samples were boiled for 10 min, and proteins were separated by
SDS-PAGE. For virion lysates, cell culture supernatants were collected
72 h after transfection by removal of cellular debris through
centrifugation at 3000 rpm for 10 min in a Sorvall RT 6000B and
ﬁltration through a 0.2-μm pore-size membrane. Virus particles were
concentrated by centrifugation through a 30% sucrose cushion at
100,000 ×g for 2 h in a Sorvall Ultra80 ultracentrifuge. Proteins were
transferred onto nitrocellulose membranes, and the membranes were
probed with various primary antibodies against proteins of interest.
Secondary antibodies were alkaline phosphatase-conjugated anti-
human and anti-mouse (Jackson Immunoresearch, Inc) antibodies,
and staining was carried out with 5-bromo-4-chloro-3indolyl phos-
phate (BCIP) and nitro-blue tetrazolium (NBT) solutions prepared
from chemicals obtained from Sigma. Blots were imaged using the
FujiFilm LAS-1000 Image Station, and protein band densities were
analyzed using the spot density analysis software Image Gauge V3.41.
Immunoprecipitation
For APOBEC-HA immunoprecipitations, transfected 293T cells
were harvested and washed twice with cold PBS, then lysed with
PBS containing 0.5% Triton X-100 and protease inhibitor cocktail
(Roche, Basel, Switzerland) at 4 °C for 1 h. Cell lysates were clariﬁed by
centrifugation at 10,000 ×g for 30min at 4 °C. Anti-HA agarose (Roche)
was mixed with the pre-cleared cell lysates and incubated at 4 °C for
3 h. The reaction mixture was then washed three times with cold PBS
and eluted with 0.1 M glycine–HCl buffer, pH 2.0. The eluted materials
were subsequently analyzed by immunoblotting.
Sucrose gradient analysis
To identify the incorporation of APOBEC3C into Gag virus-like
particles (VLPs), sucrose gradients were prepared as follows: Gag VLPs
in the culture supernatants of APOBEC transfected 293T cells were
separated from cell debris by ﬁltration and ultracentrifugation
through a 20% sucrose cushion, and the VLP pellet was resuspended,
then layered onto a sucrose density gradient (20–60%). Samples were
then centrifuged at 100,000 ×g at 4 °C. The fractions of 1 ml each were
collected from the top for immunoblotting analysis.
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